5 Key Takeaways

• 1

  Evolocumab significantly reduced the risk of major cardiovascular events in high-risk diabetes patients without known significant atherosclerosis.

• 2

  In a trial with 12,257 patients, evolocumab lowered LDL cholesterol levels to a median of 52 mg/dL compared to 111 mg/dL with placebo.

• 3

  The incidence of major adverse cardiovascular events was 5% in the evolocumab group versus 7% in the placebo group, showing a 2% absolute difference.

• 4

  Evolocumab was associated with a 34% reduction in myocardial infarction and a 31% reduction in coronary heart disease death compared to placebo.

• 5

  Serious adverse events occurred in similar rates between evolocumab (25%) and placebo (26%) groups, indicating comparable safety profiles.